Product Information
FENOFIBRATE 134 MG CAPSULE is a generic product labeled by Rhodes Pharmaceuticals L.P., priced at $0.1192 per EA under NDC 42858013401. Its NADAC has been published 482 times since Jul 12, 2017.
FDA first approved this application on Apr 9, 2002.
Strength
134 mg/1
Manufacturer
Rhodes Pharmaceuticals L.P.NDC
42858013401
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FENOFIBRATEApproval Type
Generic (ANDA)
FDA Application
ANDA075753FDA Approved
4/9/2002
On Market Since
6/1/2017
Pharmacological Classes
Price Statistics
The NADAC for FENOFIBRATE 134 MG CAPSULE has been published 482 times since Jul 12, 2017, and over the history we have for it it has declined 88.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1192 per EA |
|---|---|
| All-time high | $1.0421 (Aug 16, 2017) |
| All-time low | $0.1020 (Nov 20, 2024) |
| 52-week high | $0.1338 |
| 52-week low | $0.1101 |
| Median price | $0.1562 |
| Average price | $0.2781 |
| Largest weekly change | +38.9% (Sep 23, 2020) |
| Weeks tracked | 482 |
| Tracking since | Jul 12, 2017 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rhodes Pharmaceuticals L.P. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Fenofibrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Peroxisome Proliferator Receptor alpha Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FENOFIBRATE 134 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for FENOFIBRATE 134 MG CAPSULE, manufactured by Rhodes Pharmaceuticals L.P., is $0.1192 per EA (NDC 42858013401), effective Sep 30, 2026.
How has the price of FENOFIBRATE 134 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for FENOFIBRATE 134 MG CAPSULE has declined 88.3%. It has been tracked across 482 weekly CMS publications since Jul 12, 2017.
What are the highest and lowest recorded NADAC prices for FENOFIBRATE 134 MG CAPSULE?
Since Jul 12, 2017, the NADAC for FENOFIBRATE 134 MG CAPSULE has ranged from a low of $0.1020 (Nov 20, 2024) to a high of $1.0421 (Aug 16, 2017), with a median of $0.1562 per EA.
Are there cheaper alternatives to FENOFIBRATE 134 MG CAPSULE?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as FENOFIBRATE 134 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures FENOFIBRATE 134 MG CAPSULE?
FENOFIBRATE 134 MG CAPSULE (NDC 42858013401) is labeled by Rhodes Pharmaceuticals L.P., and CMS classifies it as a generic product.